Today on the website I have aspired to summarize in a somewhat easy to understand format the data presented at the March 2011 EASL conference . It has been estimated that over 3.2 million Americans have chronic hepatitis C (I was one of them), enter the millions of patients currently sifting through the studies, abstracts, and relevant information on the new drugs to treat this virus.
The news on both telaprevir and boceprevir remain to be impressive. If we compare the raw numbers presented in the recent data on both drugs we can't help but notice the SVR in patients who failed therapy and treated with boceprevir is at 66 percent, compared to a SVR of 83 percent in patients who also failed therapy but treated with telaprevir. You can view all abstracts/information in this summary.
Other remarkable news came from the drug company Pharmasset which presented studies on the PSI-938 and PSI-7977 combination. The study was in treatment-naive, non-cirrhotic patients with genotype 1, these patients were treated with PSI-938 and PSI-7977 (Monotherapy) without pegylated-interferon and ribavirin. Patients in the study "all" achieved undetectable in short-term followup . The drugs have high barriers to resistance, and broad genotype coverage.
No comments:
Post a Comment